氨曲南治疗急性肾盂肾炎疗效及安全性分析

Analysis on the efficacy and safety of the treatment of acute pyelonephritis with aztreonam

目的探讨氨曲南治疗急性肾盂肾炎的疗效及安全性,为临床合理用药提供依据。方法选取辽宁省金秋医院自2013年11月至2019年2月收治的335例急性肾盂肾炎患者为研究对象,并将其分为氨曲南组(n=186)与左氧氟沙星组(n=149)。记录并比较两组患者的疗效及不良反应发生情况。结果两组患者治疗前后炎症指标的差值比较,差异无统计学意义(P>0.05)。氨曲南组、左氧氟沙星组治疗有效率分别为89.8%(167/186)、83.2%(124/149),差异无统计学意义(P>0.05)。氨曲南组、左氧氟沙星组患者不良反应发生率分别为20.4%(38/186)、10.7%(16/149),差异有统计学意义(P<0.05)。氨曲南组丙氨酸氨基转移酶、上升幅度高于左氧氟沙星组,差异有统计学意义(P<0.05)。结论氨曲南与左氧氟沙星治疗急性肾盂肾炎的疗效相当,但氨曲南安全性较左氧氟沙星差,主要为肝系统受累。

Objective To investigate the efficacy and safety of aztreonam in the treatment of acute pyelonephritis,and to provide evidence for rational clinical use.Methods A retrospective study was performed on 335 patients with acute pyelonephritis who were admitted from November 2013 to February 2019.The patients were randomly divided into the aztreonam group(n=186)and the levofloxacin group(n=149).The efficacy and safety of the two groups were recorded and compared.Results There was no significant difference between the two groups before and after treatment(P>0.05).The effective rate was 89.8%(167/186)and 83.2%(124/149),respectively,in the treatment group and the group with levofloxacin(P>0.05).The incidence of adverse reactions was 20.4%(38/186)and 10.7%(16/149),respectively,with statistically significant differences(P<0.05).The increase of alanine aminotransferase in the aztreonam group was higher than that in the group with levofloxacin(P<0.05).Conclusion Aztreonam and levofloxacin are equivalent to the treatment of acute pyelonephritis,but the safety of aztreonam is worse than levofloxacin,mainly liver damage.